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Quercetin (3,5,7,30,40-pentahydroxyflavone) is a flavone with putative ability to prevent cancer and cardiovascular diseases. Its
metabolism was evaluated in rats and human. Rats received quercetin via the intravenous (i.v.) route and metabolites were isolated
from the plasma, urine and bile. Analysis was by high-performance liquid chromatography and confirmation of species identity was
achieved by mass spectrometry. Quercetin and isorhamnetin, the 30-O-methyl analogue, were found in both the plasma and urine. In
addition, several polar peaks were characterised as sulphated and glucuronidated conjugates of quercetin and isorhamnetin. Extension
of the metabolism studies to a cancer patient who had received quercetin as an i.v. bolus showed that (Quercetin removed)
isorhamnetin and quercetin 30-O-sulphate were major plasma metabolites. As a catechol, quercetin can potentially be converted to a
quinone and subsequently conjugated with glutathione (GSH). Oxidation of quercetin with mushroom tyrosinase in the presence of
GSH furnished GSH conjugates of quercetin, two mono- and one bis-substituted conjugates. However, these species were not found
in biomatrices in rats treated with quercetin. As cyclo-oxygenase-2 (COX-2) expression is mechanistically linked to carcinogenesis,
we examined whether quercetin and its metabolites can inhibit COX-2 in a human colorectal cancer cell line (HCA-7). Isorhamnetin
and its 40-isomer tamarixetin were potent inhibitors, reflected in a 90% decrease in prostaglandin E-2 (PGE-2) levels, a marker of
COX-2 activity. Quercetin was less effective, with a 50% decline. Quercetin 3- and 7-O-sulphate had no effect on PGE-2. The results
indicate that quercetin may exert its pharmacological effects, at least in part, via its metabolites.
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Naturally occurring flavonoids in the diet are associated with
several beneficial health effects and understanding the mechanisms
underlying these effects has become the focus of much research.
Quercetin (3,5,7,30,40-pentahydroxyflavone, for structure see
Figure 1) is a prime example of such a flavonoid. Its glycosylated
form occurs in kale, French beans, broccoli, apples and especially
in onions, with an abundance as high as a quarter to half a gram
per kg (Hertog et al, 1992). On ingestion with the diet, quercetin
glycosides are rapidly hydrolysed to generate quercetin.
Epidemiological evidence links diets rich in quercetin with
decreased incidence of cardiovascular and neoplastic diseases
(Hertog et al, 1993, 1994, 1995; Hertog and Hollman, 1996; Keli
et al, 1996; Le Marchand et al, 2000). From the mechanistic
standpoint, quercetin has been shown to interact with cellular
processes in numerous ways (for a review see Nijveldt et al, 2001).
Recently, cyclo-oxygenase (COX) enzymes, especially COX-2, have
been causally implicated in the early changes associated with
carcinogenesis in a number of tissues, among which the colorectal
tract has been studied most extensively (Marnett and Dubois,
2002). A noteworthy mechanistic facet of quercetin is its ability to
interfere with COX by inhibiting COX-2 promoter activity (Mutoh
et al, 2000), COX-2 protein expression (Raso et al, 2001) and COX
enzyme activity (Formica and Regelson, 1995). In the light of its
interesting biological properties germane to anticarcinogenesis,
quercetin has been subjected to a phase I clinical trial in cancer
patients, with the aim to develop it as a cancer chemopreventive or
antineoplastic agent (Ferry et al, 1996). With respect to potential
detrimental effects on health by quercetin, it has been suggested to
possess mutagenic and carcinogenic properties (MacGregor and
Jurd, 1978; Dunnick and Hailey, 1992), and at high doses there
were indications of toxicity in humans (Ferry et al, 1996).
Quercetin shares with many naturally occurring polyhydroxy-
lated molecules poor bioavailability (Hollman and Katan, 1997),
which is probably a consequence of its rapid metabolic
transformation in the liver and gastrointestinal tract. Evidence is
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saccumulating that metabolites of dietary polyphenols may
mediate, or substantially contribute to, the pharmacological
efficacy of the parent molecule, and thus explain efficacy despite
the apparent low bioavailability, as is observed with 1,3,40-
trihydroxy-trans-stilbene (resveratrol), which is found in grapes
(Gescher and Steward, 2003). Therefore, identifying the metabo-
lites of dietary components such as quercetin and resveratrol and
defining their contribution to the pharmacological and biological
effects of the parent molecule is of great importance. The fate in
the mammalian organism of the dietary progenitor glycosides of
quercetin, such as rutin and quercetrin, has been more extensively
studied than the metabolism of quercetin itself, when administered
in aglyconic form. Quercetin is oxidatively degraded to nonflavone
phenols, probably by intestinal bacteria (Booth et al, 1956;
Douglass and Hogan, 1958; Petrakis et al, 1959). Moreover, these
fission products have been shown to possess biological activity
(Merfort et al, 1996). Most importantly, quercetin has been shown
to undergo conjugation with glucuronide and sulphate at one or
more of the five hydroxyl moieties of the flavone molecule and
methylation at positions 30or 40, thus generating isorhamnetin (30-
O-methylquercetin) and tamarixetin (40-O-methylquercetin).
These conjugates have been characterised in rat urine, bile and
plasma (Ueno et al, 1983; Manach et al, 1997; Piskula and Terao,
1998). A quercetin sulphate and two quercetin sulphate-glucur-
onides were also found in the perfused rat liver (Shali et al, 1991).
Metabolites were also identified in human plasma following the
ingestion of a complex meal rich in plant products (Manach et al,
1998, Day et al, 2001). Two pharmacokinetic studies of authentic
quercetin in humans established that it is rapidly cleared from the
organism (Gugler et al, 1975; Ferry et al, 1996).
In the light of the interest in quercetin as a potential cancer
chemopreventive or chemotherapeutic agent, we reinvestigated its
metabolism in the rat using mass spectrometric methods of
chemical identification. A particular aim of the study was to
compare the qualitative pattern observed in rat plasma with that
found in a human who had undergone treatment with quercetin in
a clinical trial (Ferry et al, 1996). In the light of the indications of
its potential nephrotoxicity demonstrated in that trial, we tested
the potential of quercetin to undergo biotransformation via
conjugation with glutathione (GSH) to a proximate nephrotox-
icant, analogous to the nephrotoxicity associated with hydro-
quinone (Peters et al, 1997), bromohydroquinone (Monks et al,
1985), 17b-estradiol (Butterworth et al, 1997) or haloalkenes
(Iverson et al, 1996). Previous reports have indicated that GSH
conjugates are formed in vitro (Awad et al, 2000, 2001; Boersma
et al, 2000; Galati et al, 2001). Furthermore, mindful of the fact that
COX activity is a potential mechanistic target of quercetin, we
compared its effect on cellular prostaglandin E-2 (PGE-2)
production with that of representative quercetin metabolites.
Overall the work was designed to contribute to the database
required for the optimisation of the clinical development of
quercetin as a potential cancer chemopreventive and/or che-
motherapeutic agent.
MATERIALS AND METHODS
Materials
The following materials were purchased from the indicated
sources. Quercetin, rutin mushroom tyrosinase, high-performance
liquid chromatography (HPLC) grade dimethyl sulphoxide
(DMSO), ammonium acetate: Sigma (Poole, UK); HPLC grade
methanol: Fisher (Loughborough, UK); isorhamnetin, tamarixetin,
quercetin 3-O-sulphate: Extrasynthese (Genay, France); and
glycerol formal: Fluka (Poole, UK). Human colon adenoma cells
(HCA-7, passage number 29) were obtained from Dr S Kirkland
(Imperial College, London, UK).
Animals, treatments and incubation conditions
Male F344 rats (200–250g) were used. For metabolite analysis in
the plasma, animals were anaesthetised with pentobarbital (6mg
per rat, i.p.), and quercetin (6.25mgkg
 1) dissolved in glycerol
formal and water 1:1 was injected intravenous (i.v.) via the lateral
tail vein (injection volume: 100ml). After 5min blood was collected
by cardiac puncture. For the analysis of metabolites in bile, the
quercetin dose was 12.5mgkg
 1 (i.v.). For the study of urinary
metabolites, quercetin dissolved in DMSO (0.5mlkg
 1) was given
by gavage (2.5gkg
 1), rats were transferred to metabolism cages
and urine was collected for up to 24h postadministration. For the
analysis of metabolites in the bile, rats were anaesthetised
(pentobarbitol) and the bile duct was cannulated. Ambient body
temperature was maintained using a heat lamp. Control animals
received the vehicle only. Experiments were conducted as
stipulated by Project Licence 80/1250 granted by the UK Home
Office. The experimental design was vetted and approved by the
Leicester University Ethical Committee for Animal Experimenta-
tion and meet the standards required by the UKCCCR guidelines
(Workman et al, 1998).
In order to generate reactive oxidation products of quercetin in
vitro, quercetin and GSH (1mM each) were incubated for 1h
(371C) with mushroom tyrosinase in ammonium acetate buffer
(0.1 M, pH 7.4).
Quercetin metabolism in a human
Blood samples were obtained from a cancer patient, at the Queen
Elizabeth Hospital (Birmingham, UK), who no longer responded to
standard therapy and had been recruited into a phase I clinical
study of quercetin. This trial has been described in detail before
(Ferry et al, 1996). Quercetin formulated in DMSO was infused i.v.
(250mgm
 2 for 5min) and blood was obtained up to 2h
postadministration. The plasma was separated and stored at
 801C.
Sample preparation and HPLC analysis
Aliquots of plasma, urine, bile or tyrosinase incubate were mixed
with twice the volume of DMSO/methanol (1:4, vv
 1). Kaempferol
(internal standard) was added and the mixture was vortexed and
centrifuged (17060g, 15min). The supernatant was removed,
diluted with water (1:1) and injected onto the HPLC column
(injection volume 50ml). Hydrolysis of glucuronide and sulphate
conjugates of quercetin in the plasma or bile was performed as
described by Ader et al (2000). In short, b-glucuronidase solution
(500U in 0.1 M ammonium acetate pH 6.8) also containing
sulphatase was added to an aliquot (0.1ml) of biofluid (acidified
with 20ml of 0.5 M acetic acid). Incubations were carried out for
30min at 371C, which furnished maximal deconjugation. Following
incubation samples were extracted for analysis.
High-performance liquid chromatography analysis was per-
formed on a Varian Prostar system, which comprised of a UV
O H
OH
O
O
OR1
OR2
OH
Quercetin R1=H & R2=H
Isorhamnetin R1=CH3 & R2=H
Tamarixetin R1=H & R2=CH
Figure 1 Structures of quercetin and its metabolites.
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sdetector (model 310), solvent delivery system (model 230) and an
autosampler (model 410) with a 100ml loop. Detection was by UV
at 375nm. Analysis of the human plasma samples was performed
as described previously (Jones et al, 1998). Analysis of extracts of
rat plasma, urine or bile involved a gradient mobile phase system
(75% 0.1 M ammonium acetate in methanol, decreased linearly to
55% for 10min and to 45% for a further 20min, at which it
remained for a further 5min). The flow rate was 1mlmin
 1.
Separation was achieved on a Hypersil BDS C18 column
(250 4.6mm
2 i.d., 5mm particle size; Hypersil, Runcorn, UK).
The mobile phase used for the analysis of GSH conjugates
consisted of the same start eluent, but the content of ammonium
acetate decreased to 55% for 20min, at which it remained for a
further 50min.
For the quantitation of quercetin in plasma stock solutions
(10mgml
 1) of quercetin and kaempferol (internal standard) were
made up (DMSO), and the calibration curve was constructed with
five concentrations of quercetin (final concentrations 1, 2, 20, 100
and 200mgml
 1). The recovery of quercetin from the plasma was
90%, and the concentrations described in the results were
corrected correspondingly.
Mass spectrometry (MS)
A Quattro Bio-Q triple stage mass spectrometer (Micromass,
Manchester, UK) fitted with pneumatically assisted electrospray
(pnESI) was coupled to a Varian 9012 pump (flow rate:
1mlmin
 1). A tee-piece was incorporated postcolumn to give a
1:7 split, so that approximately 140mlmin
 1 entered the source
region of the mass spectrometer. Standards were infused into the
mass spectrometer using a Harvard syringe pump (10mlmin
 1).
Typically, a capillary voltage of 3.78kV, HV lens voltage of 0.2kV
and a cone voltage of 46V was used. Source temperature was
1101C. Two types of experiments were conducted: (i) a scan of 50–
1300m/z, from which ion chromatograms were extracted postrun
and (ii) LC-MS/MS in which specific ions underwent dissociation
in the collision cell. Collision gas was argon. All mass spectra were
acquired in the negative ion mode.
PGE-2 levels in HCA-7 cells
HCA-7 cells were routinely cultured in Dulbecco’s MEM medium
with Glutamax (Gibco, Invitrogen Corp., UK) supplemented with
10% foetal calf serum and penicillin/streptomycin (1000 and
500Uml
 1, respectively). Cells (10
5well
 1) were incubated for 6h
with quercetin (1–75mM) or quercetin metabolites (10mM)
dissolved in DMSO. Control cultures contained DMSO only. An
aliquot (1ml) of cellular supernatant was removed from each of
the plates after 6h and analysed in duplicate for PGE-2 content
using a kit, which employs an ELISA immunoassay (Cayman
Chemical Comp., MI, USA). Experiments were repeated three
times. An initial experiment involved the incubation of 50mM
quercetin and taking samples at both 6 and 24h.
RESULTS
Metabolites of quercetin in the rat
High-performance liquid chromatography analysis of plasma and
urine samples from rats, which had received quercetin
(6.25mgkg
 1) via the i.v. route, contained quercetin (retention
time 17.5min, peak i in Figure 2) and a major metabolite
(retention time 26min, peak ii in Figure 2), which coeluted with
isorhamnetin. Peak identification was confirmed by both on-line
LC-MS and LC-MS of collected peak fractions, furnishing
deprotonated molecule ions of m/z 301 for quercetin and m/z
315 for isorhamnetin.
Figure 2 High-performance liquid chromatography chromatograms of
extracts of bile (A and B), plasma (C and D) or urine (E and F) from
control rats (B, D and F) or rats that had received quercetin either 12.5
(A) or 6.25mgkg
 1 (C) and 2.5gkg
 1 (E) via the i.v. (A and C) or oral
(E) routes. Bile was collected prior to (control) and for 20min after the
administration of quercetin; plasma samples were collected 5min after
administration of quercetin; urine samples were pooled over 8h. Control
(untreated) animals received the vehicle only via the appropriate
administration route. Symbols i and ii denote retention times of quercetin
and isorhamnetin, respectively. AU¼absorbance units. For details of
sample preparation and chromatographic analysis see Materials and
Methods. The chromatograms shown are representative of extracts
obtained from three separate animals.
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sExtracts of plasma, urine or bile from quercetin-treated animals
characteristically gave 15 to 18 extra peaks (between the retention
times of 5 and 16min) that were absent from extracts of
biomatrices obtained from untreated animals (Figure 2). On the
basis of their polarity, these species were hypothesised to
constitute sulphate and glucuronide conjugates of quercetin,
which was confirmed by their disappearance on treatment with
sulphatase and b-glucuronidase and a concomitant increase in the
size of the quercetin and isorhamnetin peaks (result not shown).
To confirm this conclusion, the extracts were analysed by LC-MS
and ion chromatograms extracted postrun. Based on the
pseudomolecular ion, 10 different types of conjugate species were
detected (Table 1). In order to illustrate the findings in Table 1,
Figure 3 shows an extracted ion chromatogram of m/z 477 of
quercetin glucuronides found in the bile. Allocation of these
structures to chromatographic peaks furnished the following
number of positional isomers: two isomers each of quercetin
sulphate, quercetin bis-sulphate, quercetin bis-glucuronide, iso-
rhamnetin sulphate and isorhamnetin bis-glucuronide, four
isomers of isorhamnetin bis-sulphate, four isomers of isorhamne-
tin glucuronide, and five isomers each of quercetin sulphate-
glucuronide and isorhamnetin sulphate-glucuronide. Of the two
isomeric quercetin sulphates found, the species characterised by a
retention time of 8.7min coeluted with authentic quercetin 30-O-
sulphate. Characterisation of urine extracts by LC-MS/MS led to
the identification of six species, quercetin, isorhamnetin, quercetin
sulphate, quercetin glucuronide, isorhamnetin glucuronide and
quercetin bis-glucuronide (Table 2). Cochromatography suggested
that the urinary quercetin sulphate was quercetin 30-O-sulphate.
In an attempt to obtain preliminary information on quercetin
levels, quercetin was quantitated in the plasma. Shortly after
administration (5min) quercetin levels in the plasma were
13.774.1mM (n¼6), beyond which time the agent disappeared
rapidly. Quercetin conjugates were present until the 90min time
point postadministration. When plasma samples were subjected to
enzymatic hydrolysis, the level of total quercetin, that is,
conjugated and unconjugated, at the 5min time point increased
to 76.9711.4mM. These results suggest that at this early time point
species derived from quercetin circulating in the blood were
predominantly quercetin glucuronides and sulphates. Bile ob-
tained from these rats showed the presence of quercetin
metabolites for up to 2h postadministration.
Metabolites of quercetin in human plasma
A patient with confirmed cancer received quercetin via the i.v.
route. Extracts of plasma obtained just prior to, and 5min after,
drug administration were analysed by HPLC (Figure 4) using an
isocratic method, in contrast to the gradient elution procedure
employed in the rat study described above. Analysis by MS of peak
eluates confirmed the inferences for quercetin, isorhamnetin and
quercetin 30-O-sulphate ([M–H]
 ¼m/z 381). When plasma from
Figure 3 Extracted ion chromatogram (m/z 477) of (A) extract of bile from control rat and (B) quercetin glucuronides from bile of rats, which received
quercetin (12.5mgkg
 1 i.v.). Retention times are those noted in Table 1.
Table 1 Deprotonated molecular ions [M–H]
  and HPLC retention
times of metabolites of quercetin identified by selected ion monitoring in
the plasma, urine and bile of rats that received quercetin (6.25mgkg
 1 i.v.)
Metabolite m/z
Number of
isomers Retention time (min)
Quercetin glucuronides 477 5 7.32, 8.76, 9.85, 10.77, 13.08
Quercetin sulphates 381 2 8.67, 14.92
Quercetin sulphate-glucuronides 557 5 4.90, 5.76, 6.40, 6.71, 6.97
Quercetin bis-sulphates 461 2 11.52, 12.30
Quercetin bis-glucuronides 653 2 5.01, 5.45
Isorhamnetin glucuronides 491 4 10.08, 10.72, 12.16, 13.48
Isorhamnetin sulphates 395 2 9.54, 14.98
Isorhamnetin bis-glucuronides 667 2 4.61, 5.30
Isorhamnetin sulphate-glucuronide 571 5 5.22, 5.86, 6.51, 6.80, 7.23
Isorhamnetin bis-sulphate 475 4 9.54, 11.18, 11.29, 11.61
HPLC¼high-performance liquid chromatography.
Table 2 Mass spectral properties of quercetin and five quercetin metabolites in the urine
Metabolite Retention time (min)
a m/z (relative intensity)
Quercetin 19.2 301(50), 151 (100), 273 (15), 179 (16), 135 (30), 121 (29), 107 (50)
Isorhamnetin 26.7 315 (10), 300 (90), 271(20), 151 (100), 107 (90)
Quercetin sulphate 15.6 381 (60), 301 (100), 179 (20), 151 (50), 107(30)
Quercetin glucuronide 9.3 477(15), 301 (100), 179 (12), 151(20)
Isorhamnetin glucuronide 12.6 491(10), 315(50), 300(100), 271(10), 151(10)
Quercetin bis-glucuronide 3.8 653 (100), 477 (20), 301 (10), 151 (10)
aOwing to the fact that this analysis was conducted over a considerable time after that shown in Table 1, the retention times shown for the sulphates and glucuronides differ from
those described in Table 1 by up to 0.8min.
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sa rat, which had received quercetin, was analysed using the
isocratic method, these three species were similarly prominent
(data not shown).
GSH conjugates of quercetin
In the light of the nephrotoxic manifestations of quercetin
observed in a clinical trial (Ferry et al, 1996), the hypothesis was
tested such that quercetin might undergo metabolic oxidation in
species reacting with GSH conjugation to furnish moieties that
could potentially be targeted specifically to the kidney. To this end,
quercetin was incubated with mushroom tyrosinase, which can
oxidise catechols to their quinones (Duckworth and Coleman,
1970). High-performance liquid chromatography analysis of an
extract of the reaction mixture furnished seven peaks eluting prior
to quercetin (Figure 5). Off-line HPLC–MS analysis afforded m/z
911 [M–H]
  for peak ‘1’, consistent with bis-glutathionyl-S-
quercetin, while peaks ‘2’ and ‘3’ furnished m/z 606 [M–H]
 ,
suggestive of glutathionyl-S-quercetin. Similar results were
obtained when horseradish peroxidase was used as an oxidising
agent instead of tyrosinase. Next, the hypothesis was tested such
that GSH conjugates also occur in rats, which had received
quercetin via the p.o. or i.v. routes. However, none of the species
observed in the in vitro incubates (Figure 5) could be detected in
extracts of plasma, urine, faeces or bile from rats. Additional
experiments in which the catabolism of GSH conjugate species was
inhibited by the coadministration of the g-glutamyl transpeptidase
inhibitor acivicin also failed to engender evidence for the
formation of such conjugates (unpublished result). These results
suggest that GSH conjugates of quercetin are not formed in the rat
in vivo at levels detectable by the HPLC method employing UV and
MS detection as described here. We cannot exclude the possibility
that more sensitive detection methods such as electrochemical
ones (Carvalho et al, 2004) may have led to quercetin GSH
conjugate identification.
Effect of quercetin metabolites on cellular PGE-2
production
Human-derived HCA-7 colon cancer cells contain significant levels
of COX protein, which has been shown to be almost exclusively
COX-2 (Sharma et al, 2001). Therefore, measurement of PGE-2 in
the cellular supernatant reflects predominantly COX-2 levels and
activity. Cells were incubated for 6h with quercetin or with
selected glycosides and metabolites, and PGE-2 levels were
determined. The IC50 for inhibition of PGE-2 production by
quercetin was found to be 10mM, and at 1mM quercetin reduced
PGE-2 levels by 30% (result not shown). The quercetin progenitor
glycoside rutin and the four quercetin metabolites isorhamnetin,
tamarixetin, quercetin 3-O-sulphate and quercetin 7-O-sulphate
were compared with quercetin in terms of their ability to inhibit
PGE-2 production (Figure 6). Cells were incubated with agents at
10mM. While rutin, quercetin 3-O-sulphate and quercetin 7-O-
sulphate failed to affect PGE-2 levels, both isorhamnetin and
tamarixetin decreased PGE-2 levels by more than 90%. It is
important to point out that the COX-inhibitory activity of
quercetin glucuronides, major quercetin metabolites in rats (Day
et al, 2001), was not explored.
DISCUSSION
The results described above allow the following four conclusions to
be drawn as to the metabolism of quercetin when administered as
authentic aglycone: (i) in the rat, quercetin undergoes metabolic
methylation and multiple conjugation reactions with activated
sulphate and glucuronide, and metabolically generated isorham-
netin is also subject to such secondary conjugation reactions; (ii)
methylated and sulphated species are metabolites of quercetin in
humans; (iii) while quercetin can be oxidised to species that
undergo reaction with GSH under in vitro conditions, such species
seem not to be generated at detectable levels in rats in vivo; (i.v.)
Figure 4 High-performance liquid chromatography chromatograms of
extracts of plasma from a patient obtained before (bottom trace) and
5min after administration (top trace) of quercetin (280mgm
 2 i.v.). Peaks
were identified on the basis of cochromatography and selected ion
monitoring MS, which afforded m/z 301 for quercetin, m/z 315 for
isorhamnetin and m/z 381 for quercetin 3-O-sulphate. AU¼absorbance
units. For details of sample preparation and chromatographic and mass
spectrometric analysis see Materials and Methods.
Figure 5 High-performance liquid chromatography chromatogram of an
extract of a mixture of quercetin (1mM), glutathione (1mM) and
mushroom tyrosinase (150Uml
 1). Mass spectral analysis performed in
the selected ion monitoring mode suggests the following peak allocation: ‘1’
bis-glutathionyl-S-quercetin (m/z 911), ‘2’ and ‘3’ glutathionyl-S-quercetin
(m/z 606) and ‘4’ quercetin. AU¼absorbance units. For details of
incubation conditions, sample preparation and chromatographic conditions
see Materials and Methods. The chromatogram shown is representative of
three separate experiments.
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smetabolic methylation of quercetin confers potent COX-inhibitory
properties onto the flavone molecule.
The pattern of conjugates generated in the rat as established
here via scrupulous metabolite characterisation by MS is in broad
agreement with previous reports in the literature on the
biotransformation of quercetin after oral administration either as
dietary glycoside or genuine aglycone (Ueno et al, 1983; Manach
et al, 1997; Piskula and Terao, 1998). Only one methylated species,
isorhamnetin (30-O-methyl quercetin), was identified here, while
its 40-isomer, tamarixetin, was not. Tamarixetin was found
previously in the plasma of rats, but only when they had received
a flavonol-free diet prior to quercetin (Manach et al, 1997), which
is consistent with its absence in the plasma of the rats studied here.
Prior to our study, conjugates of quercetin had not been described
in humans following the i.v. administration of pure quercetin.
While in the work described here metabolism data were obtained
from one human only, the results clearly hint at the possibility that
quercetin undergoes metabolic sulphation and methylation not
only in rodents but also in humans. Gross comparison of the doses
and plasma levels suggests that the plasma levels achieved in rats
immediately after i.v. injection resemble the levels achieved in the
clinical trial of quercetin in humans (Ferry et al, 1996). The
quercetin dose used in rats here in terms of body surface area
(Freireich et al, 1966) was 40.6mgm
 2 (6.25mgkg
 1), approxi-
mately 4.5% of the dose given to humans (945mgm
 2). In analogy,
the plasma level (14mM) achieved in rats 5min after quercetin
administration was approximately 5% of that found in humans
immediately after quercetin administration, which was 280mM
(Ferry et al, 1996).
In the pharmacokinetic phase I study in cancer patients,
quercetin was well tolerated (Ferry et al, 1996), and there was
evidence of pharmacodynamic activity as indicated by inhibition
of epidermal growth factor receptor phosphorylation, yet indica-
tions of nephrotoxicity were also observed. Overall, the study led
to the conclusion that poor bioavailability mitigates against the
potential of quercetin as a clinically viable therapeutic agent. The
multiple conjugation reactions that quercetin has been shown to
undergo in the work described here and previously, leading to
methylated, sulphated and glucuronidated flavones, may be
responsible for, or contribute to, its poor systemic availability.
Significantly, such conjugative metabolism does not seem to
include reaction with GSH, thus rendering the possibility unlikely
that GSH conjugates of quercetin are causally implicated in its
putative nephrotoxic potential. In addition, there is no consistent
conclusion to the effect of quercetin on cellular GSH levels by
quercetin (Nijhoff et al, 1993, CanivencLavier et al, 1996; Sahu and
Gray, 1996).
The two methylated congeners of quercetin, isorhamnetin and
tamarixetin displayed potent COX enzyme inhibition, and their
inhibitory potency was significantly higher than that of the parent
molecule, quercetin. The IC50 for COX enzyme inhibition of
quercetin has been reported to be 16mM (Formica and Regelson,
1995), and in the experimental design employed here using HCA-7
cells, it was approximately 10mM. The nature of the COX-
inhibitory activity of the two metabolites and its relative specificity
for COX-2 necessitates further investigation, as this observation
may have clinical implications. That the methylated metabolites
may conceivably play a pharmacodynamic role in the mammalian
organism is borne out by a preliminary unpublished analysis of
quercetin conjugates in bile conducted in our laboratory,
according to which a major portion of drug-derived species
generated in the rat organism was isorhamnetin.
The poor bioavailability of quercetin in the phase I clinical
evaluation (Ferry et al, 1996) led to the conclusion that
administration of quercetin may fail to furnish levels of bioactive
species sufficient to exert useful pharmacological activity. This
conclusion appears premature in the light of the fact that quercetin
undergoes avid metabolism in species that may possess pharma-
cological activity, as hinted by our finding that isorhamnetin and
tamarixetin are potent COX-2 inhibitors, at least in cells in vitro.
Consistent with the notion that quercetin metabolites may be
partially responsible for the pharmacological activity of the parent
flavonol, quercetin conjugates have previously been found to
retain, at least in part, the abilities of the parent molecule to exert
antioxidation (Da Silva et al, 1998; Manach et al, 1998) and to
inhibit xanthine oxidase and lipoxygenase (Day et al, 2000).
Furthermore, products of the metabolic fission of quercetin have
been shown to demonstrate greater antioxidant potency than their
precursor (Merfort et al, 1996).
From the mechanistic standpoint, quercetin is a multitargeted
agent and has poor bioavailability in the mammalian organism,
and it shares these properties with many diet-derived polyphenols.
The results outlined here support the supposition that metabolites
of quercetin may be involved in its bioactivity, a suggestion that
warrants further study designed to unravel the full potential of this
molecule in the prevention or treatment of disease.
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